


Transition from academia to pharma

Even Walseng

22April2022



Background

- Started working with Paul Roche at the NIH in 2004 via collaboration between the University of Oslo and the NIH.
 - Basic research on MHC-II biology
 - Received Ph.D in 2008 from UIO
 - Continued as a post-doc and research fellow until 2010, moved back to Norway due to family reasons
- Started as post-doc in Johanna Olweus's lab.
 - Started immunotherapy related work, cloning of therapeutic TCRs to be used in adoptive transfer to patients T cells. 2010-2012 (2.5 years)
- Moved back to the States, joined Christoph Rader at Scripps Florida, helped establish his new lab.
 - Worked on Bispecific T cell engagers and continued immunotherapy-related work started in Norway. 2012-2015 (3 years)



Background

- Returned to the NIH and Paul Roche's lab, continued work on MHC-II biology. 2015-2020 (5 years)
 - Main reason for moving back to the DC area was due to my wife's business contacts in this area
- Joined AZ as Scientist II. 2020-current




Key events and deciding factors:



- Recruited by former mentor at UIO to continue to work on MHC-II - safest and most obvious step due to background, familiarity etc.
- **Started as post-doc in Johanna Olweus's lab.**
 - Started immunotherapy related work, cloning of therapeutic TCRs to be used in adoptive transfer to patients T cells also collaborated on CAR-T with another group that resulted in an additional paper. 2010-2012 (2.5 years)
 - Introduced to the field of Immunotherapy – without this, my move to AZ would not have happened



Key events and deciding factors:



SCRIPPS
FLORIDA[®]
THE SCRIPPS RESEARCH INSTITUTE

- Joined Christoph Rader's lab at Scripps Florida
- Continued and expanded immunotherapy related work
 - Introduced to bispecific T cell engagers which is what I'm currently working on
 - Kept working on TCR in soluble format



Key events and deciding factors:



- Return to the NIH and Paul Roche's lab
 - Picked up where I left with main focus on MHC-II
 - **BUT** kept up collaborations in the immunotherapy field with publications and invitations to speak at conferences in this field.



**Don't be scared to explore
opportunities outside of your
comfort zone.**

